← Back to patent-cliff list
CAS 110-85-0
piperazinePiperazineDiethylenediamine1,4-Diazacyclohexane
Codes: PALB-042, OLAP-013, RIBO-012, BREX-006, VORT-004, Rifampicin-001, RANO-004, POSA-037, Urapidil-012, BT-11-002
Physicochemical properties & identification
- Appearance
- White to colourless crystals or flakes; strongly hygroscopic, with an amine odour
- Solubility
- Very readily soluble in water and ethanol; a strong base (pKa1 ≈ 5.6 / pKa2 ≈ 9.8)
- Storage
- Seal under nitrogen and protect from moisture; keep away from acids and oxidising agents
Applications
- · Pharmaceutical building block: the core amine source for piperazine-ring CNS drugs such as aripiprazole, brexpiprazole and cariprazine
- · Raw material for the anthelmintic piperazine salts (citrate / phosphate)
- · CO2 capture (activator in MDEA formulations); epoxy curing agent
Application context (from source-drug indications)
Breast cancerPalbociclibEndometrial cancerOlaparibCastration-resistant prostate cancerOlaparibProstate cancerOlaparibPeritoneal cancerOlaparibEpithelial ovarian cancerOlaparibFallopian tube cancerOlaparibBreast cancerRibociclib SuccinateSchizophreniaBrexpiprazoleAlzheimer's diseaseBrexpiprazoleAgitationBrexpiprazoleDepressionBrexpiprazoleDepressive disorderBrexpiprazoleMajor depressive disorderBrexpiprazoleMajor depressive disorderVortioxetine HydrobromidePostoperative painVortioxetine HydrobromideCannabis dependenceVortioxetine HydrobromideAnxietyVortioxetine HydrobromideAnxiety disorderVortioxetine HydrobromideDepressionVortioxetine HydrobromideMycobacterium tuberculosis infectionEthambutol Hydrochloride/Rifampicin/IsoniazidAngina pectorisRanolazineMyocardial infarctionRanolazineAmyotrophic lateral sclerosisRanolazineStable anginaRanolazineCrohn's diseaseRanolazineInflammatory bowel diseaseRanolazineCandidiasisPosaconazoleAspergillus infectionPosaconazoleFungal infectionPosaconazoleOral candidiasisPosaconazoleCoccidioidomycosisPosaconazoleHistoplasmosisPosaconazoleMycobacterium tuberculosis infectionRifampicinMycobacterium leprae infectionRifampicinPulmonary tuberculosisRifampicinMeningococcal meningitisRifampicinCOVID-19RifampicinRespiratory viral infectionRifampicinHypertensionUrapidil hydrochlorideUlcerative colitisOmilancorCrohn's diseaseOmilancorEosinophilic oesophagitisOmilancor
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Palbociclib | Tier A — Act now | 2027 |
| Olaparib | Tier A — Act now | 2028 |
| Ribociclib Succinate | Tier A — Act now | 2029 |
| Brexpiprazole | Tier A — Act now | 2029 |
| Vortioxetine Hydrobromide | Tier B — Position early | - |
| Ethambutol Hydrochloride/Rifampicin/Isoniazid | Tier C — Watch / trade | - |
| Ranolazine | Tier C — Watch / trade | - |
| Posaconazole | Tier C — Watch / trade | - |
| Rifampicin | Tier C — Watch / trade | - |
| Urapidil hydrochloride | Tier C — Watch / trade | - |
| Omilancor | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate→5-bromo-2-nitropyridine→tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate→piperazine→1-(6-nitropyridin-3-yl)piperazine→PALB-044→(Z)-tert-butyl 4-(6-(2,3-bis(tert-butoxycarbonyl)guanidino)pyridin-3-yl)piperazine-1-carboxylate→1-(5-(piperazin-1-yl)pyridin-2-yl)guanidine hydrochloride→(E)-methyl 2-acetylbut-2-enoate→6-acetyl-4-amino-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-one→6-acetyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-one→chlorocyclopentane→6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-one→methyl 3-oxobutanoate
3-hydroxyisobenzofuran-1(3H)-one→2-fluoro-5-formylbenzonitrile→(Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile→2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid→cyclopropanecarbonyl chloride→2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzonitrile→cyclopropyl(piperazin-1-yl)methanone hydrochloride→piperazine
5-bromo-2,4-dichloropyrimidine→cyclopentanamine→5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine→prop-2-yn-1-ol→3-(2-chloro-4-(cyclopentylamino)pyrimidin-5-yl)prop-2-yn-1-ol→(2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol→dimethylamine→2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide→tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate→tert-butyl 4-(6-((7-cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate→5-chloro-2-nitropyridine→piperazine→1-(6-nitropyridin-3-yl)piperazine→tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
7-hydroxyquinolin-2(1H)-one→1-bromo-4-chlorobutane→7-(4-chlorobutoxy)quinolin-2(1H)-one→1-(benzo[b]thiophen-4-yl)piperazine hydrochloride→4-bromobenzo[b]thiophene→piperazine
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | 2-Fluoro-5-formylbenzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]benzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin -1-yl)Methyl)benzoic acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 1-(Cyclopropylcarbonyl)piperazine hydrochloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 3-oxo-1,3-dihydroisobenzofuran-1-ylphosphonic acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 5-broMo-2-chloro-N-cyclopentylpyriMidin-4-aMine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | Tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | PD 0332991 HCl Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-Chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic
acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6- carboxamide Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.